-
公开(公告)号：US20220363670A1
公开(公告)日：2022-11-17
申请号：US17125335
申请日：2020-12-17
Applicant: NOVARTIS AG
Inventor： Simona Cotesta , Marc Gerspacher , Catherine Leblanc , Edwige Liliane Jeanne Lorthiois , Bo Liu , Rainer Machauer , Robert Mah , Christophe Mura , Pascal Rigollier , Nadine Schneider , Stefan Stutz , Andrea Vaupel , Nicolas Warin , Rainer Wilcken
IPC: C07D403/14 , C07D405/14 , C07D417/14 , C07D401/14 , C07D471/04 , C07D413/14 , C07D487/04
Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof; a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.
-
公开(公告)号：US09822092B2
公开(公告)日：2017-11-21
申请号：US14508285
申请日：2014-10-07
Applicant: Novartis AG
Inventor： Claus Ehrhardt , Leslie Wighton McQuire , Pascal Rigollier , Olivier Rogel , Michael David Shultz , Ruben Alberto Tommasi
IPC: A61K31/402 , C07D207/30 , C07D333/22 , A61K31/381 , C07D213/50 , A61K31/4409 , C07D231/56 , A61K31/416 , A61K45/06
CPC classification number: C07D333/22 , A61K31/18 , A61K31/381 , A61K31/402 , A61K31/416 , A61K31/437 , A61K31/4402 , A61K31/4409 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/55 , A61K45/06 , C07C311/16 , C07C311/29 , C07C311/39 , C07C311/46 , C07C317/24 , C07C323/67 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D207/20 , C07D207/30 , C07D207/333 , C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/80 , C07D209/82 , C07D211/06 , C07D211/14 , C07D211/24 , C07D213/40 , C07D213/50 , C07D213/61 , C07D221/16 , C07D223/04 , C07D231/56 , C07D235/06 , C07D235/08 , C07D241/04 , C07D265/30 , C07D295/112 , C07D295/116 , C07D295/192 , C07D333/18 , C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D471/04 , C07D487/04
Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
-
Patent Agency Ranking
公开(公告)号：US20230365571A1
公开(公告)日：2023-11-16
申请号：US18044455
申请日：2021-09-15
Applicant: Novartis AG
Inventor： Trixi Brandl , Claus Ehrhardt , Robert Epple , Christian Markert , Pascal Rigollier , Juraj Velcicky
IPC: C07D487/04
CPC classification number: C07D487/04
Abstract: The present invention relates to tricyclic compounds comprising a diazepinone moiety which are effective in inhibiting Sppl2a (signal peptide peptidase like protease 2a), to pharmaceutical compositions containing such inhibitors, and to methods of using such inhibitors and compositions.
-
公开(公告)号：US20130096105A1
公开(公告)日：2013-04-18
申请号：US13690274
申请日：2012-11-30
Applicant: NOVARTIS AG
Inventor： Ruben Alberto Tommasi , Michael David Shultz , Leslie Wighton McQuire , Pascal Rigollier , Olivier Rogel , Claus Ehrhardt
IPC: A61K31/5375 , A61K31/18 , C07D213/40 , A61K31/4402 , C07D211/06 , A61K31/451 , C07D241/04 , A61K31/495 , C07D471/04 , A61K31/437 , C07D265/30 , C07D223/04 , A61K31/55 , A61K45/06 , C07C311/29
CPC classification number: C07D333/22 , A61K31/18 , A61K31/381 , A61K31/402 , A61K31/416 , A61K31/437 , A61K31/4402 , A61K31/4409 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/55 , A61K45/06 , C07C311/16 , C07C311/29 , C07C311/39 , C07C311/46 , C07C317/24 , C07C323/67 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D207/20 , C07D207/30 , C07D207/333 , C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/80 , C07D209/82 , C07D211/06 , C07D211/14 , C07D211/24 , C07D213/40 , C07D213/50 , C07D213/61 , C07D221/16 , C07D223/04 , C07D231/56 , C07D235/06 , C07D235/08 , C07D241/04 , C07D265/30 , C07D295/112 , C07D295/116 , C07D295/192 , C07D333/18 , C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D471/04 , C07D487/04
Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
Abstract translation: 本发明提供式（I）化合物：所述化合物是MMP-2和/或MMP-8和/或MMP-9和/或MMP-12和/或MMP-13的抑制剂，因此 可以用于治疗以MMP-2，/或MMP-8和/或MMP-9，和/或MMP-12和/或MMP-13异常活性为特征的疾病或疾病。 因此，式（I）化合物可用于治疗由MMP-2和/或MMP-8和/或MMP-9和/或MMP-12和/或MMP- 13。 最后，本发明还提供药物组合物。
-
公开(公告)号：US11702409B2
公开(公告)日：2023-07-18
申请号：US17125335
申请日：2020-12-17
Applicant: NOVARTIS AG
Inventor： Simona Cotesta , Marc Gerspacher , Catherine Leblanc , Edwige Liliane Jeanne Lorthiois , Bo Liu , Rainer Machauer , Robert Mah , Christophe Mura , Pascal Rigollier , Nadine Schneider , Stefan Stutz , Andrea Vaupel , Nicolas Warin , Rainer Wilcken
IPC: C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04
CPC classification number: C07D403/14 , C07D401/14 , C07D405/14 , C07D413/14 , C07D417/14 , C07D471/04 , C07D487/04 , C07B2200/13
Abstract: The present invention provides a compound of formula (I) or a stereoisomer thereof, or an atropisomer thereof, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt of a stereoisomer thereof, or a pharmaceutically acceptable salt of an atropisomer thereof;
a method for manufacturing said compound, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition comprising said compound.-
公开(公告)号：US08975439B2
公开(公告)日：2015-03-10
申请号：US13690274
申请日：2012-11-30
Applicant: Novartis AG
Inventor： Ruben Alberto Tommasi , Michael David Shultz , Leslie Wighton McQuire , Pascal Rigollier , Olivier Rogel , Claus Ehrhardt
IPC: C07C311/16 , A61K31/18 , C07D207/333 , C07D209/12 , C07C317/24 , C07D295/112 , A61K45/06 , C07D403/04 , C07D409/04 , A61K31/55 , C07D209/82 , C07D235/06 , C07D241/04 , C07C323/67 , C07D211/14 , C07D265/30 , C07D211/06 , C07D213/61 , C07D213/50 , C07D471/04 , C07D209/14 , C07D211/24 , C07D209/08 , C07D209/10 , C07D333/22 , A61K31/4402 , C07D401/04 , C07D295/116 , C07C311/46 , C07D223/04 , C07D333/18 , C07D413/04 , C07D221/16 , C07D295/192 , C07D207/20 , A61K31/451 , C07D209/80 , A61K31/437 , C07D213/40 , C07C311/29 , C07D487/04 , C07D231/56 , A61K31/495 , C07C311/39 , C07D235/08 , A61K31/5375
CPC classification number: C07D333/22 , A61K31/18 , A61K31/381 , A61K31/402 , A61K31/416 , A61K31/437 , A61K31/4402 , A61K31/4409 , A61K31/451 , A61K31/495 , A61K31/5375 , A61K31/55 , A61K45/06 , C07C311/16 , C07C311/29 , C07C311/39 , C07C311/46 , C07C317/24 , C07C323/67 , C07C2601/02 , C07C2601/08 , C07C2601/14 , C07C2602/08 , C07D207/20 , C07D207/30 , C07D207/333 , C07D209/08 , C07D209/10 , C07D209/12 , C07D209/14 , C07D209/80 , C07D209/82 , C07D211/06 , C07D211/14 , C07D211/24 , C07D213/40 , C07D213/50 , C07D213/61 , C07D221/16 , C07D223/04 , C07D231/56 , C07D235/06 , C07D235/08 , C07D241/04 , C07D265/30 , C07D295/112 , C07D295/116 , C07D295/192 , C07D333/18 , C07D401/04 , C07D403/04 , C07D409/04 , C07D413/04 , C07D471/04 , C07D487/04
Abstract: The present invention provides a compound of formula (I): said compound is inhibitor of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13, and thus can be employed for the treatment of a disorder or disease characterized by abnormal activity of MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12 and/or MMP-13. Accordingly, the compound of formula (I) can be used in treatment of disorders or diseases mediated by MMP-2, and/or MMP-8, and/or MMP-9, and/or MMP-12, and/or MMP-13. Finally, the present invention also provides a pharmaceutical composition.
Abstract translation: 本发明提供式（I）化合物：所述化合物是MMP-2和/或MMP-8和/或MMP-9和/或MMP-12和/或MMP-13的抑制剂，因此 可以用于治疗以MMP-2，/或MMP-8和/或MMP-9，和/或MMP-12和/或MMP-13异常活性为特征的疾病或疾病。 因此，式（I）化合物可用于治疗由MMP-2和/或MMP-8和/或MMP-9和/或MMP-12和/或MMP- 13。 最后，本发明还提供药物组合物。
-
公开(公告)号：US20130149281A1
公开(公告)日：2013-06-13
申请号：US13764509
申请日：2013-02-11
Applicant: NOVARTIS AG
Inventor： Trixi Brandl , Jiping Fu , Francois Lenoir , David Thomas Parker , Michael Patane , Branko Radetich , Prakash Raman , Pascal Rigollier , Mohindra Seepersaud , Oliver Simic , Aregahegn Yifru , Rui Zhang
CPC classification number: A61K38/07 , A61K38/00 , A61K38/06 , A61K45/06 , C07D209/96 , C07D401/12 , C07D401/14 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14 , C07D487/10 , C07D491/20 , C07D495/10 , C07D498/04 , C07D498/10 , C07K5/06034 , C07K5/06078 , C07K5/06165 , C07K5/0808 , C07K5/0812 , C07K5/101 , C07K5/1016
Abstract: The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound.
Abstract translation: 本申请描述了通过向有需要的受试者施用药学有效量的式I化合物与另外的HCV调节化合物组合来治疗HCV相关疾病的方法。
-
-
-
-
-
-
Search Results
7
records
(took 0.018 seconds)
